Orphan status for ChemGenex
Tuesday, 20 January, 2009
Melbourne’s ChemGenex has been granted orphan drug status for its apoptopic drug omacetaxine mepesuccinate from the US FDA.
The orphan drug status is for use in myelodysplastic syndromes, a range of bone marrow stem cell disorders. May sufferers die from infection while some develop acute myelogenous leukaemia.
The drug is also currently in Phase II trials for chronic myeloid leukaemia. The drug induces apoptosis by inhibiting protein synthesis and is being trialled in people with a mutation in the T3151 gene, who are often resistant to the front-line drug imatinib (Glivec).
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
